Biotech & Life Sciences in China Update: NMPA Approves First Foreign CAR-T Therapy — Key Takeaways
In February 2025, China’s National Medical Products Administration (NMPA, 国家药品监督管理局, Guójiā Yàopǐn Jiāndū Guǎnlǐ Jú) granted marketing authorization to Breyanzi (lisocabtagene maraleucel), the first fully foreign-owned chimeric antigen receptor T-cell therapy (CAR-T, 嵌合抗原受体T细胞疗法, qiǎnhé kàngyuán shòutǐ T xìbāo liáofǎ) to enter the Chinese market under standard registration. The approval caps a 14-month review process and opens a regulatory door for 12 foreign CAR-T candidates currently active in China’s clinical trial pipeline.
Approval Details and Clinical Significance
Breyanzi, developed by Bristol Myers Squibb (BMS), was approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more prior lines of systemic therapy. The NMPA based its decision on positive bridging data from a China-specific phase II trial enrolling 128 patients at 9 hospitals in Beijing, Shanghai, and Guangzhou. The trial reported a 73% overall response rate (ORR) and a 54% complete remission (CR) rate at 12-month follow-up, comparable to global pivotal study results.
This approval is significant because it follows NMPA’s 2024 reformed Drug Registration Regulation (药品注册管理办法, Yàopǐn Zhùcè Guǎnlǐ Bànfǎ, 2024 revision), which introduced an expedited pathway for cell and gene therapies that have already secured approval in at least one ICH (International Council for Harmonisation) member region. Breyanzi leveraged this pathway, cutting the standard review timeline — typically 24–36 months — by nearly half.
Market Implications for Foreign Biotech
China’s cell therapy market is projected to reach RMB 42.5 billion by 2028, up from RMB 7.8 billion in 2023 — a compound annual growth rate (CAGR) of 33%. Domestic CAR-T therapies, such as Yescarta (Fosun Kite, approved 2021) and Carteyva (JW Therapeutics, approved 2021), currently hold 82% market share by volume. Breyanzi’s entry signals a shift toward competition from multinational corporations (MNCs) and may pressure domestic pricing, which currently averages RMB 1.2–1.5 million per infusion.
The approval also sends a signal to the 12 foreign CAR-T therapies now in various phases of China clinical trials — including candidates from Johnson & Johnson (Carvykti), Novartis (Kymriah), and CRISPR Therapeutics (exagamglogene autotemcel). Analysts at ChinaBio expect 3–4 additional NMPA filings from MNCs within 2025–2026. However, manufacturing localization remains a hurdle because NMPA requires cell therapies to be produced at a licensed facility within mainland China, not in Hong Kong or Macau.
Pricing Landscape in China
| Therapy (Brand) | Developer | Approval Year | China Price per Infusion (RMB) | Reimbursement Status |
|---|---|---|---|---|
| Yescarta (axicabtagene ciloleucel) | Fosun Kite (JV) | 2021 | 1,200,000 | Not reimbursed; VBC covers 11 cities |
| Carteyva (relmacabtagene autoleucel) | JW Therapeutics | 2021 | 1,290,000 | Not reimbursed; patient assistance only |
| Breyanzi (lisocabtagene maraleucel) | Bristol Myers Squibb | 2025 | 1,350,000 (est.) | Pending; under NRDL negotiation |
| Kymriah (tisagenlecleucel) | Novartis | Pending (Phase III ongoing) | TBD | — |
Table note: NRDL = National Reimbursement Drug List; VBC = Volume-Based Procurement pilot for innovative therapies in select cities. Breyanzi pricing is estimated based on company disclosures in November 2024.
Regulatory Pathway Comparison
Breyanzi’s approval under the reformed pathway differs markedly from earlier domestic CAR-T clearances. Before 2024, foreign cellular therapies faced a two-track system: either form a joint venture (as Yescarta did with Fosun Pharma) or conduct a full China phase I–III program at a cost of RMB 800 million–1.2 billion over 5–7 years. Under the new regulation, foreign therapies with ICH-region approval can submit a streamlined dossier if they provide confirmatory bridging data from a China phase II trial with at least 80 patients and a minimum 12-month safety follow-up.
Key Differences Under the 2024 Reform
- Prior Track (pre-2024): Full China phase I–III (average 5.5 years), mandatory local manufacturing JV, 24–36 month NMPA review.
- New Track (2024+): China phase II bridging (2–3 years), allowed wholly foreign-owned manufacturing (WFOE, 外商独资企业, wàishāng dúzī qǐyè) at NMPA-inspected facility, 12–18 month NMPA review.
- Cost savings: The new pathway reduces clinical development costs by approximately 40–50% (from RMB 800 million to RMB 400–500 million), according to a December 2024 analysis by Deloitte China.
However, NMPA now requires real-world evidence (RWE) commitments as a post-marketing condition. Breyanzi’s approval includes a mandate to track all treated patients in a registry for 5 years, with quarterly updates to CDE. This is a first for any foreign cell therapy in China and will likely become standard.
Decision Framework for Foreign Executives
The Breyanzi approval provides a fresh playbook for biotech leaders evaluating China market entry for cell and gene therapies.
- If your therapy has ICH-region approval and post-phase II data: Choose the 2024 expedited pathway. Budget RMB 400–500 million for China bridging studies and WFOE manufacturing setup. Timeline: 3–4 years to market.
- If your therapy is preclinical or early phase I: Choose a local joint venture or out-license partner. The new pathway does not waive China-first trials for candidates without prior global approval. Full China development will cost RMB 800 million–1.2 billion and take 5–7 years.
- If you are pricing your therapy above RMB 1.5 million per infusion: Choose a clear NRDL negotiation strategy (volume-based pricing) or a tiered patient access program. The Chinese market has limited tolerance for 100% out-of-pocket luxury pricing in cell therapy after government pushback on Yescarta’s cost in 2022–2023.
Key Takeaways for Foreign Executives
- Timeline compression is real. Breyanzi’s 14-month NMPA review is 40% faster than the historical average for foreign biologics in China. Expect the CDE to maintain this cadence for therapies with strong bridging data.
- WFOE manufacturing is now viable. NMPA accepts wholly foreign-owned production facilities — a change driven by the Cell and Gene Therapy Provisions (effective 2023). BMS built its Suzhou facility in 22 months. Budget RMB 150–200 million for a 2,000 sqm CAR-T manufacturing plant in a bio-park such as Zhangjiang (Shanghai) or Suzhou Industrial Park.
- The pricing ceiling is tightening. With three domestic and one foreign CAR-T now approved, hospital procurement committees will benchmark prices. Expect average net prices to settle at RMB 1.1–1.3 million per infusion by 2027, including NRDL discounts of 30–50%.
- RWE is a new gating condition. Plan for a registry system from day one. NMPA will prioritize renewal of conditional approvals based on data quality.
- Competition will intensify by 2027. At least 10 foreign and 15 domestic CAR-T candidates are expected to file NMPA applications by end-2027. First-mover advantages (as BMS now has) will narrow quickly.
NEXT STEPS
- Audit your own pipeline against the 2024 pathway. Review which of your candidates have ICH-region approval or late-phase data. Assess whether your early-stage candidates could benefit from the new China phase II bridging option. See our Biotech Regulation Guide for a full walkthrough of NMPA filing options.
- Evaluate WFOE vs. JV for manufacturing. If your therapy is CAR-T or an autologous cell therapy, local production is compulsory. Compare costs, timelines, and IP considerations across the two structures. Read our WFOE vs. JV Decision Matrix for biotech.
- Engage the NMPA early on RWE planning. Schedule a pre-submission meeting (type B, fee: RMB 50,000) with the CDE to discuss registry design, endpoints, and timelines. NMPA accepts virtual engagement. Learn more in NMPA Meeting Strategy for Foreign Biotech.
— China Gateway 360 —
Remote China market entry support, built around execution.
